Skip to content

SG&A at other companies

Abbott logo
AbbottABT
$3.74B+22.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.03B+18.0%
Boston Scientific logo
Boston ScientificBSX
$1.78B+11.5%
Medtronic logo
MedtronicMDT
$3.06B+12.4%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$118.21M+10.0%
ITG
Integer HoldingsITGR
$58.71M+14.8%

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%
Free cash flow-$14.6M-7.8%

Valuation

See full
Market cap$1.77B+38.4%

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s SG&A?
Pulse Biosciences, Inc. (PLSE) reported SG&A of $6.59M in Q1 2026.
How has Pulse Biosciences, Inc.'s SG&A changed year-over-year?
Pulse Biosciences, Inc.'s SG&A decreased by 14.7% year-over-year, from $7.73M to $6.59M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.